THROMBOCYTHEMIA, ESSENTIAL

Clinical trials for THROMBOCYTHEMIA, ESSENTIAL explained in plain language.

Never miss a new study

Get alerted when new THROMBOCYTHEMIA, ESSENTIAL trials appear

Sign up with your email to follow new studies for THROMBOCYTHEMIA, ESSENTIAL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 2 Not yet recruiting 1 Not yet finished but already full! 1 Completed 1

Bomedemstat shows promise for Long-Term control of rare blood cancers

Disease control Completed

This study looked at the long-term safety and effectiveness of the drug bomedemstat in 81 people with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Participants had already taken bomedemstat in an earlier study and continued treatment to see how well it cont…

Matched conditions: THROMBOCYTHEMIA, ESSENTIAL

Phase: PHASE2 • Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) • Aim: Disease control

Last updated May 18, 2026 12:07 UTC

THROMBOCYTHEMIA, ESSENTIAL

Get alerted when new THROMBOCYTHEMIA, ESSENTIAL trials appear

Bomedemstat shows promise for Long-Term control of rare blood cancers